GlaxoSmithKline Raises Bet on Potential Blockbuster AIDS Drug With New Shionogi, Inc. Deal

Published: Oct 29, 2012

GlaxoSmithKline has raised its bet on a promising drug for HIV/AIDS by redrawing a deal with Japan's Shionogi which gives it a much bigger economic interest in the new product.

Dolutegravir, a once-daily drug that has performed strongly in clinical trials, is seen by analysts as a potential multi-billion-dollar-a-year seller and a strong competitor to treatments from market leader Gilead Sciences.

Back to news